Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $140.26 USD
Change Today +1.23 / 0.88%
Volume 34.1K
EW On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 9:38 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

edwards lifesciences corp (EW) Snapshot

Open
$139.56
Previous Close
$139.03
Day High
$140.89
Day Low
$139.33
52 Week High
07/29/15 - $159.00
52 Week Low
10/16/14 - $97.07
Market Cap
15.1B
Average Volume 10 Days
1.4M
EPS TTM
$4.17
Shares Outstanding
107.5M
EX-Date
--
P/E TM
33.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for EDWARDS LIFESCIENCES CORP (EW)

edwards lifesciences corp (EW) Related Businessweek News

No Related Businessweek News Found

edwards lifesciences corp (EW) Details

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function in surgical and intensive care settings; minimally invasive continuous cardiac output monitoring systems and non invasive hemodynamic monitor for real time beat-to-beat information; pulmonary artery catheters; continuous venous oximetry catheter for measuring central venous oxygen saturation; and sensor-catheter sets that measures a critically ill patient's volumetric hemodynamic parameters. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

9,100 Employees
Last Reported Date: 02/20/15
Founded in 1999

edwards lifesciences corp (EW) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $758.8K
Corporate Vice President of EMEA, Canada and ...
Total Annual Compensation: $604.8K
Corporate Vice President of Heart Valve Thera...
Total Annual Compensation: $469.7K
Corporate Vice President of Transcatheter Hea...
Total Annual Compensation: $466.5K
Compensation as of Fiscal Year 2014.

edwards lifesciences corp (EW) Key Developments

Edwards Lifesciences Corp. Announces the Resignation of Robert A. Ingram as Board of Director

Edwards Lifesciences Corp. announced that Robert A. Ingram has retired from the company's Board of Directors. Ingram joined Edwards' board in 2003 and has chaired the Compensation and Governance Committee, as well as served on the Audit Committee.

Edwards Lifesciences Corp. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015; Revised Earnings Outlook for the Full Year 2015; Provides Earnings Outlook for Third Quarter of 2015

Edwards Lifesciences Corp. reported unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company’s net sales were $616.8 million against $575.1 million a year ago. Income before provision for income tax was $142.2 million against $813.2 million a year ago. Net income was $112.7 million or $1.02 per diluted share against $547.0 million or $5.09 per diluted share a year ago. Non-GAAP net income was $124.4 million or $1.13 per diluted share against $94.0 million or $0.88 per diluted share a year ago. Cash flow from operating activities for the quarter was $170.1 million. After capital spending of $18.4 million, free cash flow was $151.7 million. Non-GAAP sales were $622 million, reflecting 18% underlying growth as compared to last year. The strengthening of the U.S. dollar continued to have a significant negative impact on reported sales. For the six months, the company’s net sales were $1,207.1 million against $1,097.5 million a year ago. Income before provision for income tax was $304.7 million against $890.5 million a year ago. Net income was $236.1 million or $2.14 per diluted share against $607.3 million or $5.63 per diluted share a year ago. Non-GAAP net income was $248.1 million or $2.25 per diluted share against $176.1 million or $1.63 per diluted share a year ago. The company continues to expect full year 2015 total sales to be between $2.3 billion to $2.5 billion. The company is increasing its guidance for full year 2015 diluted earnings per share, excluding special items, to a range of $4.30 to $4.40, from its previous range of $4.10 to $4.30. If foreign exchange rates remain at current levels, the company now expects its full year gross profit rate to be between 76% and 77%, excluding special items. Assuming current rates, as foreign exchange positions expire, the company expects to lose the significant positive contribution to gross profit in 2016. For the full year, the company expects net interest expense to be approximately $10 million. The company continues to expect full year tax rate, excluding the impact of special items, to be between 21% to 23%. For the full year 2015, the company expects free cash, flow excluding special items, to be at the high end of its previous range of $375 million to $425 million. For the third quarter of 2015, at current foreign exchange rates, the company projects total sales to be between $580 million and $620 million, and diluted earnings per share, excluding special items, to be between $0.92 and $1.00.

Edwards Lifesciences Corp. to Report Q2, 2015 Results on Jul 28, 2015

Edwards Lifesciences Corp. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Jul 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EW:US $140.47 USD +1.44

EW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $190.73 USD -1.13
Endo International PLC $76.39 USD +1.43
Hologic Inc $38.53 USD +0.65
Intuitive Surgical Inc $515.00 USD +3.87
Mettler-Toledo International Inc $298.05 USD +0.87
View Industry Companies
 

Industry Analysis

EW

Industry Average

Valuation EW Industry Range
Price/Earnings 33.8x
Price/Sales 6.0x
Price/Book 6.4x
Price/Cash Flow 33.1x
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EDWARDS LIFESCIENCES CORP, please visit www.edwards.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.